Additionally, the 36-month beta value for MTNB is 1.61. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for MTNB is 4.70M and currently, short sellers hold a 14.53% ratio of that float. The average trading volume of MTNB on January 31, 2025 was 549.45K shares.
MTNB) stock’s latest price update
Matinas Biopharma Holdings Inc (AMEX: MTNB)’s stock price has gone decline by -8.84 in comparison to its previous close of 0.65, however, the company has experienced a -1.17% decrease in its stock price over the last five trading days. globenewswire.com reported 2025-01-10 that BEDMINSTER, N.J., Jan. 10, 2025 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) announces that on January 6, 2025, it received a NYSE American LLC notice indicating that the Company has fallen below certain NYSE American continued listing standards because it failed to hold its annual meeting of stockholders for the fiscal year ending on December 31, 2024, as set forth in Section 704 of the NYSE American Company Guide.
MTNB’s Market Performance
Matinas Biopharma Holdings Inc (MTNB) has experienced a -1.17% fall in stock performance for the past week, with a 13.90% rise in the past month, and a -81.56% drop in the past quarter. The volatility ratio for the week is 16.61%, and the volatility levels for the past 30 days are at 22.59% for MTNB. The simple moving average for the past 20 days is -6.40% for MTNB’s stock, with a -87.94% simple moving average for the past 200 days.
Analysts’ Opinion of MTNB
Piper Sandler gave a rating of “Overweight” to MTNB, setting the target price at $3 in the report published on January 27th of the previous year.
MTNB Trading at -1.49% from the 50-Day Moving Average
After a stumble in the market that brought MTNB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -97.26% of loss for the given period.
Volatility was left at 22.59%, however, over the last 30 days, the volatility rate increased by 16.61%, as shares surge +13.90% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.00% lower at present.
During the last 5 trading sessions, MTNB fell by -1.17%, which changed the moving average for the period of 200-days by -94.46% in comparison to the 20-day moving average, which settled at $0.6303. In addition, Matinas Biopharma Holdings Inc saw 15.69% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for MTNB
Current profitability levels for the company are sitting at:
- 20.08 for the present operating margin
- 1.66 for the gross margin
The net margin for Matinas Biopharma Holdings Inc stands at 19.28. The total capital return value is set at -1.19. Equity return is now at value -108.57, with -83.91 for asset returns.
Based on Matinas Biopharma Holdings Inc (MTNB), the company’s capital structure generated 0.16 points at debt to capital in total, while cash flow to debt ratio is standing at -5.52.
Currently, EBITDA for the company is -22.82 million with net debt to EBITDA at 0.34. When we switch over and look at the enterprise to sales, we see a ratio of 3.85. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.53.
Conclusion
In conclusion, Matinas Biopharma Holdings Inc (MTNB) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
